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Intimin-␥ is an outer membrane protein of enterohemorrhagic Escherichia coli (EHEC) O157:H7 that is required for the organism to adhere tightly to HEp-2 cells
and to colonize experimental animals. Another EHEC
O157:H7 protein, the Transferred intimin receptor (Tir),
is considered the primary receptor for intimin-␥. Nevertheless, Tir-independent binding of intimin-␥ to HEp-2
cells has been reported. This observation suggests the
existence of a eukaryotic receptor(s) for intimin-␥. In
this study, we sought to identify that receptor(s). First,
we determined by equilibrium binding titration that the
association of purified intimin-␥ with HEp-2 cells was
specific and consistent with a single host cell receptor.
Second, we isolated a protein from lysates of HEp-2 cells
that bound intimin-␥ and subsequently identified this
molecule as nucleolin, a protein involved in cell growth
regulation that can be cell surface-expressed. Third, we
established that purified intimin-␥ and nucleolin were
co-localized on the surface of HEp-2 cells and that the
site of EHEC O157:H7 attachment was associated with
regions of nucleolin expression. Finally, we demonstrated that mouse anti-nucleolin sera significantly decreased the adherence of EHEC O157:H7 to HEp-2 cells.
From this, we conclude that nucleolin is the HEp-2 cell
receptor for intimin-␥ expressed by EHEC O157:H7.

Escherichia coli that make one or more types of Shiga toxin
(collectively called Shiga toxin-producing E. coli (STECs))1 are
estimated to cause 110,000 diarrheal illnesses a year in the
United States (1). E. coli O157:H7 is responsible for about
74,000 of these cases. E. coli O157:H7 belongs to a subset of
STEC designated enterohemorrhagic E. coli (or EHEC) that
not only makes Shiga toxins but also produces a protein called
intimin (2) that facilitates the organisms attachment to the
lumen of the bowel and evokes an attach and efface lesion at
the site of the bacterial-enterocyte interface (3). The genes for
production of the A/E lesion, which include intimin and Tir (4),
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are located on an ⬃43-kb pathogenicity island in the O157:H7
chromosome called the locus of enterocyte effacement (LEE)
(5). In addition to intimin and Tir, the LEE contains genes for
a type III secretion system (6) as well as for a number of E.
coli-secreted proteins that, along with Tir, are injected into the
host cell (reviewed in Ref. 7). Acting in concert, these proteins
expressed from the LEE induce the host cell to produce an
actin-rich pedestal that appears to cup the bacterium and anchor it into place (reviewed in Ref. 8).
EHEC O157:H7 intimin belongs to a family of adhesin molecules that are produced by bacteria capable of evoking A/E
lesions, i.e. enteropathogenic E. coli (EPEC), Hafnei alvei,
Citrobacter rodentium, as well as EPEC-like bacteria of rabbits
and dogs (3, 9, 10). Members of the intimin family of adhesins
are also related to the invasins of Yersinia enterocolitica and
Yersinia pseudotuberculosis (11). Not all regions of the intimins
and invasin share equivalent amino acid sequence homologies.
Indeed, the transmembrane domains of these proteins are relatively conserved, but the sequences of the carboxyl-terminal
regions that contain the putative host cell binding domain are
divergent (12, 13). For the Yersinia invasins, these carboxylterminal regions bind to the eukaryotic ␤1 integrin receptor
(14), whereas for the EPEC and EHEC O157:H7 intimins the
carboxyl-terminal domain is required for direct binding to the
LEE-encoded intimin receptor Tir (15). Currently, intimins
have been classified into at least five different types (␣, ␤, ␥, ␦,
and ⑀) based on homologies in the carboxyl termini of the
proteins (16, 17). The intimin of EHEC O157:H7 is of the
gamma type and will hereafter be designated intimin-␥.
Several lines of evidence indicate that intimin-␥ is the primary adhesin of EHEC O157:H7. First, intimin-␥ is required
for adherence of EHEC O157:H7 to tissue culture cells and
human pediatric explants (18 –20). Second, the protein is necessary for EHEC O157:H7-evoked A/E lesion formation and
intestinal colonization of gnotobiotic pigs and colostrum-deprived calves (21–23). Third, disruption of the intimin-␥ eae
gene abolishes adherence of EHEC (18). Fourth, antiserum
raised against intimin-␥ blocks binding of EHEC O157:H7 to
cultured epithelial cells (22–24). The probable role of intimin-␥
as an adherence factor for EHEC O157:H7 has prompted an
intense search for its putative host cell receptor. Based on both
the homology between invasin and the intimins and the capacity of invasin to mediate Y. enterocolitica and Y. pseudotuberculosis invasion of the host cells by binding to ␤1 chain integrins (14), the integrin-binding properties of intimins have
been investigated. Although intimins can bind to ␤1 chain
integrins in enzyme-linked immunosorbent assays or on the
surface of lymphocytes (27), the current consensus in the literature is that intimin association with ␤1 chain integrins is not
essential for adherence (28). Rather, Finlay and co-workers (4,
29) convincingly demonstrated that EPEC intimin-␣ as well as
EHEC O157:H7 intimin-␥ bind to the cognate bacterial Tir
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protein that is injected into the host cell by the bacteria. However, the pattern of phosphorylation of EHEC O157:H7 Tir
after injection into the host cell is different from that of EPEC
Tir, an observation that may suggest differences in the function
of these proteins within the eukaryotic cell (29). Disruption of
the tir gene in both EPEC and EHEC abolishes adherence, and
this finding supports the critical role of the interaction between
Tir and intimin during infection (4, 29).
That intimin binds to Tir on the host cell surface is incontrovertible. Nevertheless, there is also indirect evidence for a
eukaryotic intimin receptor. The findings in favor of such a
cellular receptor are as follows. First, enteropathogenic and
enterohemorrhagic E. coli preferentially colonize different portions of the gastrointestinal tract, i.e. these microbes infect the
small intestine and large intestine, respectively (3). This specific tissue tropism appears to be influenced by intimin, as work
by Tzipori et al. (21) has shown that in gnotobiotic pigs the
location of EPEC colonization can be altered based on the type
of intimin (EPEC intimin-␣ or EHEC intimin-␥) the bacteria
express. Furthermore, experiments with human intestinal tissue demonstrate that bacteria that express intimin-␥ adhere
selectively to the follicle-associated epithelium above the Peyer’s patches, whereas the same bacteria that express intimin-␣
adhere to both the small intestinal mucosa and the follicleassociated epithelium of Peyer’s patches (30). Second, as inferred earlier, the genetic sequences that encode the host cell
binding domains of the different intimin types are far more
divergent than the surrounding, more conserved sequences
(31). The sequence divergence in the host cell binding regions of
the intimins most likely represents changes advantageous for
colonization of a particular niche by the different LEE-containing bacteria (12, 13). A final line of evidence that suggests that
intimin may have a host cell surface receptor other than Tir
comes from mutational analysis of the host cell binding domain
of intimin-␣. Mutations in this region of the adhesin disrupt the
capacity of the bacteria to adhere to the host cell but do not
interfere with the in vitro interaction between intimin and Tir
(32, 33). If Tir functions as the sole intimin receptor, such
mutations should not affect bacterial adherence. One caveat to
this interpretation is that these mutations may not disrupt
binding in vitro but may destabilize the interaction between
intimin and Tir in vivo sufficiently to prevent adherence (34).
If intimin does bind to a eukaryotic receptor in a manner
analogous to that of the invasin-integrin interaction, then purified intimin should bind to the surface of host cells. In fact,
several groups have investigated the binding of purified intimin to tissue culture cells with varying results. Frankel and
colleagues (12, 35) reported that fusion proteins that contained
the carboxyl-terminal domain of intimin bind in a punctate
manner across the HEp-2 cell surface, whereas De Vinney et al.
(29) and Liu et al. (36) have found that purified intimin does not
bind to HeLa cells unless Tir is first inserted into the host cell
membrane by preinfection with an intimin-deletion strain. In
accordance with the methodology described by Frankel et al.
(12), our experience has been that both holointimin-␥ and its
carboxyl-terminal domain alone can bind to HEp-2 tissue culture cells in the absence of Tir.2 For the research presented in
this paper, our goals were to quantify the binding of purified
intimin-␥ to HEp-2 cells, identify the intimin-␥ receptor on the
cells, and determine whether this interaction is of biological
significance with respect to the adherence of EHEC O157:H7 to
these epithelial cells.

2

L. J. Gansheroff and A. D. O’Brien, unpublished data.
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EXPERIMENTAL PROCEDURES

Bacterial Strains and Plasmids—EHEC O157:H7 strain 86-24 was
isolated in 1986 from a patient in Seattle, WA and was kindly provided
by Dr. Phil Tarr (Children’s Hospital and Medical Center, Seattle, WA).
DNA isolated from this strain served as a template for amplification of
both the eae (intimin-␥) and tir genes. The histidine-tagged expression
plasmids pEB313 (encodes all but the first 34 amino acids (potential
signal sequence) of the eae gene) and pMW103 (encodes the carboxylterminal third of intimin) as well as the E. coli strain L172 that was
used for overexpression of intimin-␥ proteins have been described previously (24, 37). The entire tir gene with some flanking sequence was
amplified from EHEC O157:H7 strain 86-24 by PCR with primers that
incorporated XbaI restriction sites into the wild-type sequence (31)
(GTCATCTAGAGCCGTTTATCGACTACGTGC upstream and CAGAAGCTCTAGAGTTGCCATCC downstream). Restriction enzyme digest patterns of the PCR product were consistent with that of the
published sequence for tir (31). The fragment was then ligated into
pBluescript II KS (Stratagene) to permit overexpression of the Tir
protein. This construct was designated pTir and was subsequently
transformed into the E. coli strain BL21 (Novagen) that contains a
chromosomally encoded T7 polymerase gene under control of the lac
repressor. Plasmid p166 was generously provided by Drs. William Day
and Anthony Maurelli (Uniformed Services University of the Health
Sciences, Bethesda, MD). This pBAD-based plasmid (38) contains the
gene for the green fluorescent protein (39) inserted behind an arabinose-inducible promoter. Plasmid p166 was transformed into EHEC
strain 86-24 by electroporation. GFP expression was induced with 1%
arabinose and was used as a means of visualizing bacterial adherence
to HEp-2 cells (see “Bacterial Adherence Assay” below for details).
Culture Cell—HEp-2 (ATCC CCL23) human laryngeal epithelial
cells were maintained by serial passage in EMEM (BioWhittaker),
supplemented with 10% fetal calf serum, 20 mM L-glutamine, 100 g/ml
gentamicin, 10 units/ml penicillin G, and 10 g/ml streptomycin (called
complete EMEM). Cells were grown at 37 °C in a humidified atmosphere of 5% CO2. For subconfluent HEp-2 cell monolayers, 8-well
chamber slides (Lab-Tek) were seeded with 6 ⫻ 104 cells/well in complete EMEM and incubated for no more than 24 h (⬃80% confluent)
before use. Confluent HEp-2 cell monolayers were prepared according
to a method previously described for Vero cells (40). HEp-2 cells were
seeded into 8-well chamber slides at a density of 3 ⫻ 104 cells/well and
incubated for 72 h. The medium in each well was then removed and
replaced with complete EMEM that contained 1% fetal calf serum. Cells
were maintained under these conditions for up to 48 h prior to use.
Protein Purification—Luria broth cultures (250 ml) of E. coli strain
L172 transformed with pEB313, pMW103, or E. coli strain BL21 transformed with pTir were grown at 37 °C to an optical density (A600 nm) of
0.8, and protein was expression induced by the addition of 1 mM isopropyl-␤-thiogalactopyranoside. Four h after induction, the bacteria
were harvested by centrifugation and lysed by the addition of 5 M
guanidine hydrochloride, pH 8. Insoluble protein was removed from the
lysate by centrifugation. Proteins were then purified from the clarified
lysates as follows. Each histidine-tagged intimin-␥ protein was purified
by passage over a nickel affinity resin (Ni-NTA, Qiagen). Columns were
washed with 10 column volumes of 8 M urea, pH 8, followed by 10
column volumes of 8 M urea, pH 6.5. Tagged proteins were eluted by the
addition of 2 column volumes of 8 M urea, pH 4.5. The eluted proteins
were dialyzed thoroughly against 100 mM sodium phosphate monobasic
buffer at pH 4.5, which allowed intimin-␥ to remain soluble at high
concentration. Proteins were stored frozen at ⫺20 °C in dialysis buffer
until needed. The concentrations of the histidine-tagged intimin-␥ proteins were determined by absorbance at 280 nm using an extinction
coefficient of 119710 M⫺1 cm⫺1 calculated from the amino acid composition of the intimin-␥ sequence. Please note that for purposes of brevity, these nickel affinity-purified, histidine-tagged intimin-␥ proteins
are referred to in this article as intimin-␥ or intimin-␥ carboxyl-terminal third. We have no reason to suspect that addition of the histidine
tag at the amino terminus of the proteins alters in any way the adhesion
mediated by the carboxyl-terminal extracellular domain of intimin.
The Tir protein was extracted from isopropyl-␤-thiogalactopyranoside-induced cultures with 5 M urea and concentrated from clarified
lysates by 60% ammonium sulfate precipitation, and the precipitate
was dialyzed against 100 mM sodium phosphate buffer, pH 7. The
dialysate was then subjected to anion-exchange column chromatography with DEAE-Sephadex A-50 (Amersham Biosciences, Inc.). Protein
was eluted from the column with 0.45 M NaCl and was ⬃80% pure as
assessed by SDS-PAGE.
Nucleolin was purified from HEp-2 cells as follows. Cells were lysed
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in 10 mM phosphate buffer, pH 6.5, that contained 250 mM NaCl, 0.5%
Triton X-100, and 150 g/ml phenylmethylsulfonyl fluoride (Roche Molecular Biochemicals). Soluble nucleolin was extracted from solution
with DEAE Sephadex A-50 (Amersham Biosciences, Inc.) and eluted
from the resin with lysis buffer that contained 500 mM NaCl. Eluted
proteins were precipitated with 30% ammonium chloride and dialyzed
against 50 mM phosphate buffer, pH 6.5, that contained 250 mM NaCl.
The dialysate was then subjected to DEAE-Sepharose CL-6B (Amersham Biosciences, Inc.) anion-exchange column chromatography. The
column was washed with phosphate buffer containing 300 mM NaCl,
and protein was eluted from the column with a linear salt gradient from
300 to 500 mM NaCl. Fractions that contained the highest concentration
of nucleolin were pooled. This material appeared homogeneous on Coomassie-stained SDS-PAGE and ran as one spot on a two-dimensional
gel.
Antibodies and Production of Antisera—An IgG monoclonal antibody
against intimin-␥ was prepared in collaboration with Virion Systems
Inc. (Rockville, MD)3 Polyclonal antiserum against intimin-␥ was produced in conjunction with Duncroft, Inc. (Lovettsville, VA) by immunization of a sheep with purified intimin-␥ mixed with Freund’s adjuvant.4 Anti-nucleolin monoclonal antibody C23 (MS-3) was purchased
from Santa Cruz Biotechnology, Inc. Polyclonal antibodies against
HEp-2 cell nucleolin were raised in 6 – 8-week-old BALB/c female mice
by intraperitoneal injection of protein eluted from an SDS-polyacrylamide gel slice and mixed with adjuvant. Serum samples from mice
were tested by Western blot analysis for reactivity to HEp-2 cell nucleolin, and immunoreactive serum samples were pooled. Normal mouse
serum was obtained from nonimmunized mice of the same lot. In
conjunction with Cocalico Biologicals, Inc. (Reamstown, PA), polyclonal
antiserum against Tir was produced in a rabbit by subcutaneous injection of electroeluted Tir mixed with adjuvant. Secondary antibodies
were obtained from the following suppliers: HRP-conjugated goat antimouse IgG from Bio-Rad Laboratories; FITC-conjugated goat antimouse IgG and Texas Red-conjugated donkey anti-sheep IgG from
Jackson ImmunoResearch Laboratories.
Immunoblot Analysis and Protein Overlay Assays—Proteins used in
this study were separated by molecular weight using SDS-PAGE with
a Mini-PROTEAN II Electrophoresis Cell (Bio-Rad) following standard
protocols. For two-dimensional electrophoresis, detergent-solubilized
HEp-2 proteins were separated in the first dimension by isoelectric
focusing using the Mini-PROTEAN Tube Cell (Bio-Rad) and then in the
second dimension by SDS-PAGE. Protein gels were blotted onto Optitran nitrocellulose membranes (Schleicher & Schuell) with a Trans-Blot
SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad). Membranes were
blocked with PBS, pH 7.4, that contained 5% powdered milk and 0.2%
Tween 20. For Western analyses, both primary and secondary antibodies were diluted in 5% powdered milk, 0.2% Tween 20 in PBS. The
anti-nucleolin monoclonal antibody was used at a 1:5,000 dilution and
the anti-intimin monoclonal antibody at a 1:7,000 dilution. The HRPconjugated goat anti-mouse IgG secondary antibody was diluted
1:20,000. Immunoreactive proteins were detected with enhanced chemiluminescence (ECL Plus, Amersham Biosciences, Inc.). For intimin-␥
protein overlay assays, purified intimin-␥ was diluted to a concentration of 3 g/ml in PBS, pH 6.5 that contained 2% powdered milk and
0.2% Tween 20. This solution was incubated with blots of SDS-PAGE
separated HEp-2 proteins that were not heated or reduced before electrophoresis. Intimin-␥ that had bound to specific HEp-2 cell proteins
was detected with anti-intimin monoclonal antibodies as described
above. For nucleolin protein overlay assays, HEp-2 cells were extracted
with 50 mM phosphate buffer pH 8 that contained 0.1% Triton X-100,
and the soluble proteins were diluted into PBS, pH 6.5, that contained
2% powdered milk and 0.2% Tween 20. This solution was incubated
with immunoblots of intimin-␥ (full-length and carboxyl-terminal third)
that had been separated by SDS-PAGE without heating or reduction of
the samples. Nucleolin from the HEp-2 extract that had bound to
intimin-␥ or the carboxyl-terminal third of intimin-␥ was detected with
anti-nucleolin monoclonal antibodies per the above protocol.
Intimin-␥ Affinity Chromatography—Intimin-␥ was covalently
linked by means of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimiide
hydrochloride (Sigma) to carboxylate-modified polystyrene particles
(Seradyn, Inc.). Bovine serum albumin was covalently linked to the
same type of particles as a control to assess the level of nonspecific
binding of HEp-2 cell extracts to that matrix. HEp-2 cells were lysed in

3
M. R. Wachtel, L. J. Gansheroff, R. F. Schuman, and A. D. O’Brien,
unpublished data.
4
M. Mills, E. M. Twiddy, and A. D. O’Brien, unpublished data.

a 10 mM phosphate buffer, pH 8, that contained 136 mM NaCl, 1 mM
MgCl, 0.5 mM CaCl, 0.5% Triton X-100, and 150 g/ml phenylmethylsulfonyl fluoride. The pH of the cell extract was then reduced to 6 by a
dropwise addition of HCl. Insoluble protein was removed by centrifugation, and the clarified supernatant was mixed gently with the intimin-␥⫺linked polystyrene particles for 1 h at 25 °C. The particles
were removed from solution and washed extensively with buffer. HEp-2
cell proteins that had bound to intimin-␥ were eluted by rinsing particles with a 50 mM phosphate buffer, pH 7, that contained 250 mM NaCl.
Eluted proteins were separated by SDS-PAGE and stained with Coomassie Brilliant Blue.
Protein Sequencing—A HEp-2 cell protein with an apparent molecular mass of 110 kDa was selected for amino acid sequencing because it
displayed the most intense immunoreactive band in intimin-␥ protein
overlay assays. Following intimin-␥ affinity purification, this protein
was excised from an SDS-polyacrylamide gel and sent to the Protein
Chemistry Laboratory, Department of Biochemistry, Texas A&M University. In that laboratory, the protein in the gel slice was reduced,
alkylated, and digested with Endo-LysC. Peptides were extracted and
purified by reverse-phase, narrow bore, high-pressure liquid chromatography. The purified peptides were then subjected to automated Edman protein sequencing on a Hewlett Packard G1000A Automated
Protein Sequencer. Peptide sequences obtained by these methods were
used as input for a BLAST search (41) of the available data bases.
Intimin-␥ Binding to HEp-2 Cells—Purified intimin-␥ was labeled
with biotinamidocaproate N-hydroxysuccinimide ester (Sigma) in 0.1 M
sodium borate buffer, pH 9, at a ratio of 1 g of ester/25 g of protein.
Samples were incubated at room temperature for 2 h, and then the
reaction was stopped by the addition of 5 mM ammonium chloride.
Excess label was removed by extensive dialysis of the mixture against
50 mM phosphate buffer, pH 5. Labeled intimin-␥ was diluted into
RPMI 1640 medium that contained 20 mM sodium phosphate monobasic and 0.5% bovine serum albumin (Sigma). For the titration of
intimin-␥ binding to HEp-2 cells, 96-well tissue culture plates (Costar)
were seeded with 2 ⫻ 104 cells/well in complete EMEM and used 24 or
48 h later. Intimin-␥ over a range of concentrations (0.05–50 g/ml) was
incubated with these cells for 1 h. In a separate experiment, labeled
intimin-␥ at the same range of concentrations was incubated with
HEp-2 cells in the presence of a large excess (500 g/ml) of unlabeled
intimin-␥ under the same conditions. Unbound protein was then removed from all wells by aspiration and the cells washed gently with
PBS. Bound protein and HEp-2 cells were removed from the wells by
the addition of SDS sample buffer (25 mM Tris, pH 6.8, 1% SDS, 5%
glycerol). Total protein from the wells was separated by SDS-PAGE and
blotted onto nitrocellulose. Labeled intimin-␥ that had bound to the
HEp-2 cell surface was visualized by incubation of the blots with a
streptavidin-HRP conjugate (Amersham Biosciences, Inc.) diluted
1:10,000 in PBS with 5% powdered milk and 0.2% Tween 20, followed
by chemiluminescent detection and autoradiography as described
above. To generate a standard curve against which to estimate the
concentration of intimin-␥ bound to HEp-2 cells, various concentrations
of labeled intimin-␥ were subjected to SDS-PAGE and then immunoblotted. Autoradiographs of the intimin Western blots were digitized
and the protein concentration determined by densitometric analysis
performed on a Macintosh computer using the public domain NIH
Image program (developed at the National Institutes of Health).5
Bacterial Adherence Assay—Infection of HEp-2 cells with EHEC
strain 86-24 was done essentially as described previously (37) with
minor modifications. HEp-2 cell monolayers were infected with strain
86-24 taken from a Luria broth static overnight culture and diluted into
EMEM that contained 1% mannose and 10 mM sodium phosphate. After
2.5–3 h of infection, cells were washed with PBS to remove nonadherent
bacteria and fresh EMEM buffer was added. After an additional 3 h of
incubation, the infected cells were washed thoroughly with PBS to
remove all bacteria that were not intimately adherent. Cells were then
fixed with 3% formalin for 20 min. For some experiments, the cells were
then permeabilized with 0.1% Triton X-100 for 4 min. To induce GFP
expression in bacteria that had been transformed with p166, 1% arabinose was substituted for 1% mannose in the adherence buffer. For
antibody blocking experiments, anti-nucleolin and normal mouse sera
were diluted 1:100 in adherence medium. Identical samples of antinucleolin and normal mouse sera were selectively depleted of antinucleolin antibodies by adsorption on strips of nitrocellulose that contained purified nucleolin protein. Antibodies specific for nucleolin were
eluted from the nitrocellulose strips by the addition of 100 mM glycine

5
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buffer, pH 2, followed by neutralization of the eluted material with 100
mM Tris buffer, pH 8. All samples (polyclonal sera, depleted sera, and
eluted antibodies) were heated to 56 °C for 30 min to inactivate complement. These samples were then added to cells 1 h prior to infection
with strain 86-24(p166). Four h after infection, nonadherent bacteria
were washed from the cells. The number of adherent GFP-expressing
bacteria were counted from an image obtained under fluorescence.
Indirect Immunofluorescence Microscopy—Nucleolin expressed on
the surface of HEp-2 cells was detected as follows. Mouse anti-nucleolin
polyclonal sera (pooled from 4 mice) were diluted 1:100 into culture
medium and added to cells for at least 1 h. Cells were then formalin
fixed and, if necessary, permeabilized. Anti-nucleolin antibodies were
detected by incubation for 1 h with a FITC-conjugated goat anti-mouse
IgG antibody diluted 1:40 in PBS that contained 3% bovine serum
albumin. To demonstrate intimin-␥ binding to cells, 5 g/ml purified
intimin-␥ was incubated with HEp-2 cells as described above. After cells
were formalin-fixed, sheep anti-intimin-␥ diluted 1:50 in PBS that
contained 3% bovine serum albumin was added to the cells for 1 h.
Intimin-␥䡠anti-intimin complexes were detected by incubation of the
cells for 1 h with Texas Red-conjugated donkey anti-sheep IgG-specific
antibodies that had been diluted 1:40 in PBS with 3% bovine serum
albumin. Tir localized beneath adherent bacteria or intimin-␥ on the
surface of adherent bacteria were detected as follows. HEp-2 cells were
infected with EHEC strain 86-24 as described above. Following formalin fixation and Triton X-100 permeabilization, infected cells were incubated for 1 h with either sheep anti-intimin-␥ or rabbit anti-Tir sera
diluted 1:50 or 1:400, respectively, in PBS with 3% bovine serum albumin. Bound antibodies were then detected with the appropriate Texas
Red-conjugated secondary antibody diluted in the same buffer. Samples
in this research were examined with an Olympus BX60 system microscope with a BX-FLA reflected light fluorescence attachment. All images were obtained with a SPOT RT CCD digital camera (Diagnostic
Instrument, Inc.).
RESULTS

Quantitation of Intimin-␥ Binding to the HEp-2 Cell Surface—To begin to define the interaction between intimin-␥ and
any potential eukaryotic receptor, we analyzed the association
between biotin-labeled intimin-␥ and HEp-2 cells over a range
of protein concentrations. Examination of the kinetics of association for intimin-␥ with HEp-2 cells (data not shown) demonstrated that equilibrium between the bound and free protein
was established after ⬃40 min. Therefore, biotinylated intimin-␥ was incubated with the cells for 1 h in all subsequent
binding studies to provide sufficient time to establish equilibrium between the bound and free protein. The amount of biotinylated intimin-␥ that bound to cells was determined by detection with a streptavidin-HRP conjugate. The binding of
purified intimin-␥ to subconfluent HEp-2 cells (24 h post-seeding) was saturable at the highest concentrations of purified
protein tested (Fig. 1A, closed circles). In addition, these same
concentrations of biotinylated intimin-␥ were incubated with
HEp-2 cells in the presence of excess (0.5 mg/ml) unlabeled
intimin-␥ (Fig. 1A, open circles) to provide an estimate of nonspecific binding. That the majority of labeled intimin-␥ binding
could be blocked by unlabeled protein suggests that the association between intimin-␥ and the HEp-2 cell surface is specific.
Scatchard analysis of this titration (Fig. 1C, circles) yielded a
straight (non-curved) line, a finding that signified that intimin-␥ bound to a single receptor. The slope of this line gave a
dissociation constant of 84 nM (⫾ 8 nM) for binding of purified
intimin-␥ to the surface of HEp-2 cells. HEp-2 cells used at 48 h
post-seeding were fully confluent and bound significantly less
purified intimin-␥ than the subconfluent cells tested at 24 h
(Fig. 1B, closed squares), whereas the amount of nonspecifically
bound protein (Fig. 1B, open squares) was similar to that seen
for the cells examined at 24 h post-seeding. The Scatchard plot
of these data (Fig. 1C, squares) yielded a slope similar to that
calculated for the binding of intimin-␥ to subconfluent HEp-2
cells (93 nM (⫾ 10 nM)). Based on the x-intercepts of the Scatchard plots for these two binding titrations, we estimated that
the concentration of intimin-␥ binding sites on the surface of

FIG. 1. Titration of intimin-␥ binding to the HEp-2 cell surface
receptor. A range of concentrations of biotinylated intimin-␥ (x axis)
was added to subconfluent (A) or confluent (B) monolayers of HEp-2
cells. These titrations were performed without (closed symbols) or with
(open symbols) an excess (0.5 mg/ml) of unlabeled intimin-␥ to provide
an estimate of nonspecific binding. The concentration of biotinylated
intimin-␥ that bound to the cell surface (y axis) was determined as
described under “Experimental Procedures.” Each point is the mean of
three independent measurements, and error bars depict one standard
error of the mean. C, Scatchard plot of the binding data for biotinylated
intimin-␥ on subconfluent (circles) and confluent (squares) HEp-2 cell
monolayers. The specifically bound protein concentration was calculated by subtracting the amount of nonspecifically bound protein (open
symbols) from the total bound protein (closed symbols) in panels A and
B. The slope of both lines gave an apparent dissociation constant of
⬃84 –93 nM (⫾10 nM). The error bars represent 15% of the value of
bound/free protein and indicate the maximum error of this calculation.

confluent HEp-2 cells was ⬃50% lower than that present on the
surface of subconfluent monolayers.
Identification of the HEp-2 Cell Receptor for Intimin-␥—
Initially we made the assumption that the receptor for intimin-␥ was most likely a protein or glycoprotein. Based on this
prediction, we then used protein overlay assays as an initial
approach to identify intimin-␥ receptor candidates in HEp-2
cell extracts. For these studies, HEp-2 cell lysates were separated on SDS-polyacrylamide gels and the proteins blotted onto
nitrocellulose. These blots were blocked and then incubated
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FIG. 2. Purified intimin-␥ or the carboxyl-terminal domain of
intimin-␥ bind preferentially to a HEp-2 cell protein identified
as nucleolin. A, extracts of HEp-2 cellular proteins were separated by
SDS-PAGE and stained with Coomassie Blue (lane 1) or blotted onto
nitrocellulose and used in protein overlay experiments with purified
histidine-tagged intimin-␥ (3 g/ml). HEp-2 cell proteins that bound
intimin-␥ were detected with anti-intimin-␥ monoclonal antibodies
(lane 2). Coomassie Blue stained SDS-polyacrylamide gels of total Triton X-100-solubilized HEp-2 cell proteins before (lane 3) and after
incubation and elution from an intimin-␥ affinity matrix (lane 4). The
protein that had the strongest affinity for intimin-␥ was identified as
nucleolin by internal amino acid sequencing. The same 110-kDa protein
band recognized in lanes 2 and 4 was detected by probing affinitypurified protein with a commercially available anti-nucleolin monoclonal antibody (lane 5). Molecular weight markers (in kDa) are indicated on the right; the arrow indicates the 110-kDa nucleolin protein. B,
purified intimin-␥ (lanes 1 and 3) or the carboxyl-terminal third of
intimin-␥ (lanes 2 and 4) were subjected to SDS-PAGE (without reducing agents), blotted onto nitrocellulose, and incubated with Triton
X-100 soluble HEp-2 cell extracts that contained nucleolin (lanes 1 and
2) or with buffer (lanes 3 and 4). Bound nucleolin was detected with an
anti-nucleolin monoclonal antibody. Molecular weight markers (in kDa)
are indicated on the right; the arrows indicate intimin-␥ (97 kDa) or the
carboxyl-terminal third of intimin-␥ (35 kDa).

with purified intimin-␥. After extensive washing, HEp-2 cell
proteins to which intimin-␥ had bound were detected with an
anti-intimin-␥ monoclonal antibody. Although numerous
HEp-2 cell proteins were apparent in Coomassie Blue-stained
gels (Fig. 2A, lane 1), only a few cellular proteins were found to
bind intimin-␥ (Fig. 2A, lane 2). In particular, one HEp-2 cell
protein with an apparent molecular mass of 110 kDa produced
an intense signal in overlay assays, a finding indicating that
this protein species had bound significant amounts of purified
intimin-␥. Several other proteins also bound intimin-␥, but the
intensities of these signals were considerably less than that
produced by the 110-kDa protein species (Fig. 2A, lane 2).
These other signals may represent less avid or less specific
binding of intimin-␥, and the identification of these proteins
was not pursued further.
Next, we used affinity chromatography with intimin-␥ as an
adsorbent in an attempt to purify the HEp-2 cell receptor
identified in protein overlay assays. Detergent-soluble HEp-2
cell proteins (Fig. 2A, lane 3) were incubated with intimin-␥
linked to a solid support. The 110-kDa protein was eluted from
the intimin-␥ affinity matrix (Fig. 2A, lane 4) with an increase
in salt concentration or an increase in pH. Binding of this
110-kDa protein was not observed on a control matrix that
contained only covalently linked bovine serum albumin. The
intimin-␥ affinity matrix bound the greatest amount of the
110-kDa protein when incubated with HEp-2 cell extracts at a
pH of 5.5 to 6, whereas no detectable binding of the 110-kDa
protein to the matrix was evident at pH 8 or above. To identify

the protein that bound to immobilized intimin-␥, the 110-kDa
band was cut from a polyacrylamide gel and subjected to proteolytic cleavage, and two protein fragments were sequenced by
Edman degradation. The sequences obtained for these two
peptides were KGIAYIEFK and KEVFEDAAE. A BLAST
search (41) of the relevant data bases with these peptide sequences revealed homology to the eukaryotic protein nucleolin.
The peptide sequences we obtained were identical to human
nucleolin (GenBank accession number AAA59954) between
amino acids 410 and 437. Nucleolin has a predicted molecular
mass of 77 kDa but has been reported to display an aberrant
electrophoretic mobility of 110 kDa (42).
That we had identified nucleolin, a protein that functions in
ribosome biogenesis and cell growth (reviewed in Refs. 42 and
43), as the putative HEp-2 cell receptor for intimin-␥ was
initially perplexing given that nucleolin is typically localized to
the nucleolus of cells (44, 45). However, several reports have
indicated that nucleolin can be expressed at the cell surface
(46 – 49) and that surface-expressed nucleolin may serve as a
cellular receptor for several viruses (50 –52). Moreover, nucleolin is highly expressed and comprises up to 5% of the total
nuclear protein in actively dividing cells, but its expression in
the nucleus and on the cell surface of resting cells is largely
down-regulated (45, 53, 54). The latter observation is in keeping with our finding that the binding of intimin-␥ to HEp-2 cells
is optimal in subconfluent cells and is decreased in confluent
monolayers of cells (Fig. 1). For these reasons, we concluded
that nucleolin was a credible candidate as a putative HEp-2 cell
receptor for intimin-␥. Two findings from the isolation of
nucleolin as the intimin-␥ receptor lead us to believe that the
association between these two proteins may involve electrostatic
interactions. First, intimin-␥ carries a large net positive charge
(13), whereas nucleolin bears a large net negative charge (55).
Second, the effects of salt and buffer pH on the binding and
elution profile of nucleolin from the intimin-␥ affinity matrix
indicates that the disruption of electrostatic interactions interferes with the association between the two proteins.
To verify that the 110-kDa protein that bound to intimin-␥
was nucleolin, a Western blot of the intimin-␥ affinity-purified
protein was probed with a commercially obtained monoclonal
anti-nucleolin antibody (Fig. 2A, lane 5). From that immunoblot, we concluded that the protein eluted from the intimin-␥
affinity column was specifically recognized by anti-nucleolin
antibody. To confirm that nucleolin was binding to intimin-␥,
we next carried out protein overlay experiments. Intimin-␥ or
intimin-␥ carboxyl-terminal third, subjected to nonreducing
SDS-PAGE and blotted onto nitrocellulose, were incubated
with HEp-2 cell extracts containing nucleolin. Nucleolin that
reacted with immobilized intimin-␥ was detected with monoclonal anti-nucleolin antibody and a HRP-conjugated antimouse IgG-specific secondary antibody. The results of this experiment are presented in Fig. 2B. Both the full-length
intimin-␥ (97-kDa protein in lane 1) and the intimin-␥ carboxylterminal third (35-kDa protein in lane 2) bound nucleolin. No
anti-nucleolin binding was detected in lanes that contained
full-length intimin-␥ (lane 3) or the intimin-␥ carboxyl-terminal
third (lane 4) incubated with buffer rather than HEp-2 cell
extracts. The smaller molecular weight protein species in lane
1 represent breakdown fragments of full-length intimin-␥. The
higher molecular weight species in lane 2 represent disulfidelinked multimers of the carboxyl-terminal third of intimin-␥.
No binding of nucleolin could be detected when intimin-␥ was
blotted under reducing conditions (data not shown). These findings confirmed that nucleolin bound to intimin-␥ and localized
the nucleolin-binding region to the carboxyl-terminal third of
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FIG. 3. Immunofluorescent staining demonstrates similarity
between the distribution of nucleolin and bound intimin-␥ on
the surface of HEp-2 cells. A, HEp-2 cell cultures were stained for
nucleolin (A1, A2, A4, and A5) with mouse anti-nucleolin polyclonal
antisera and a FITC-conjugated goat anti-mouse IgG secondary antibody. Nuclear and cytoplasmic nucleolin were stained in fixed/permeabilized cells (A1, A4), whereas surface-expressed nucleolin was stained
on nonpermeabilized cells (A2, A5). In separate wells (A3, A6), intimin-␥
bound to the cell surface was stained with sheep anti-intimin-␥ polyclonal antiserum and Texas Red-conjugated donkey anti-sheep IgG
antibody. Subconfluent cells (A1, A2, and A3) stained brightly for
nucleolin in the nucleus (A1) and on the cell surface (A2) and for bound
intimin-␥ (A3). Confluent cells (A4, A5, and A6) showed greatly reduced
nucleolin staining both in the nucleus (A4) and on the surface of the
cells (A5) and greatly reduced intimin-␥ staining (A6). B, surface-localized nucleolin (B1) and bound intimin-␥ (B2) simultaneously stained on
the surface of subconfluent HEp-2 cells. Co-localization of the two
proteins is indicated by the predominant orange-yellow color when the
red and green staining patterns were overlaid in panel B3. These
combined patterns are also shown superimposed on the phase-contrast
image of the cells in panel B4. All images were obtained at an original
magnification of 40⫻.

intimin-␥, the portion of the molecule that contains the putative host cell-binding domain.
Distribution of Nucleolin and Intimin-␥ on HEp-2 Cells Is
Similar—We reasoned that if nucleolin is indeed a receptor for
intimin-␥ on HEp-2 cells, then the distribution of these two
proteins on the surface of the cells should be similar if not
overlapping. To test this hypothesis, we began a series of immunofluorescent staining experiments to investigate the localization of nucleolin and intimin-␥ (Fig. 3). For these studies,
differentially tagged secondary antibodies were used to indirectly identify nucleolin (stained green with FITC) and intimin-␥ (stained red with Texas Red). We first compared the
immunostaining patterns of nucleolin within the HEp-2 cells
(fixed, permeabilized cells; Fig. 3, A1 and A4) and on the HEp-2
cell surface (nonpermeabilized cells; Fig. 3, A2 and A5) in both
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subconfluent (Fig. 3, A1 and A2) and confluent cells (Fig. 3, A4
and A5). The intensity of nucleolin staining both in the nucleus
and on the cell surface of subconfluent monolayers was much
greater than that seen in confluent monolayers and is consistent with the up-regulation of nucleolin expression observed in
actively dividing cells (54). In a separate experiment, purified
intimin-␥ bound to both subconfluent (Fig. 3, A3) and confluent
HEp-2 cell monolayers (Fig. 3, A6) was examined. As predicted,
subconfluent cells stained more intensely for bound intimin-␥
than did confluent cells. This growth-related difference in
nucleolin expression on the cell surface is also in keeping with
our previous observation that the intimin-␥ receptor concentration decreased as cells reached confluence (Fig. 1). Overall, the
patterns of staining for both nucleolin and intimin-␥ were similar, and both molecules appeared to be dispersed in a punctate
manner over the cell surface (compare panels A2 and A3 in Fig.
3). According to a previous report by Frankel and colleagues
(12), this punctate staining pattern is characteristic of all intimin subtypes. To show co-localization of nucleolin and intimin-␥ on the HEp-2 cell surface, we next simultaneously
stained cells for both nucleolin (Fig. 3, B1) and intimin-␥ (Fig.
3, B2). As evident by the yellow-orange color apparent after the
anti-nucleolin and anti-intimin-␥ images are superimposed
(Fig. 3, B3), nucleolin and intimin-␥ overlap in many regions on
the surface of subconfluent HEp-2 cell monolayers. When the
staining patterns of both proteins were overlaid on a phasecontrast photomicrograph of the HEp-2 cells (Fig. 3, B4), it was
clear that the staining did not cover the entire cell surface but
was restricted to discrete regions. In fact, some cells showed no
apparent staining for either protein, a result that suggests that
even in subconfluent monolayers not all HEp-2 cells express
nucleolin on the cell surface or can bind intimin-␥.
Nucleolin Is Involved in the Adherence of EHEC O157:H7 to
HEp-2 Cells—To address whether intimin-␥ on EHEC
O157:H7 interacts with nucleolin on the surface of HEp-2 cells
during bacterial adherence, a second series of indirect immunofluorescent experiments were done. A comparison of the surface expression of nucleolin in infected HEp-2 cell monolayers
(Fig. 4, A2) with the distribution of adherent bacterial microcolonies on infected cells (Fig. 4, A1) indicated a positive correlation between the regions of nucleolin expression and the
areas of bacterial attachment (Fig. 4, A3 and A4). Although
FITC-stained nucleolin was evident at the periphery of bacterial microcolonies, the nucleolin stain was not observed beneath intimately adherent bacteria. Moreover, nucleolin was
not apparent beneath the bacteria even after permeabilization
and staining of infected HEP-2 cells with anti-nucleolin antiserum (data not shown).
The absence of nucleolin staining beneath microcolonies is
unlike published reports of actin (56) and Tir (29) accumulation
beneath EHEC microcolonies. Although nucleolin appeared to
concentrate around the periphery of the microcolony (Fig. 4, B1
and B2), Tir staining was found directly beneath the adherent
bacteria (Fig. 4, B3) with very little overlap apparent between
the two proteins (Fig. 4, B4). In similar experiments with
infected HEp-2 cells double-stained for nucleolin and intimin-␥,
little or no intimin-␥ was observed in association with EHEC
microcolonies (Fig. 4, C1 and C3), whereas nucleolin was localized around adherent bacterial microcolonies (Fig. 4, C2 and
C4). Although some isolated EHEC were brightly stained with
the anti-intimin-␥ antiserum, most bacteria were not. These
results suggest that intimin-␥ expression is down-regulated in
adherent EHEC, similar to reports of reduced intimin-␣ expression in EPEC after intimate adherence (57).
EHEC O157:H7 Adherence Is Partially Blocked by Polyclonal
Antiserum against Human Nucleolin—Next we asked whether
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FIG. 4. EHEC O157:H7 adherence coincides with regions of
nucleolin expression on the surface of HEp-2 cells. Subconfluent
HEp-2 cell monolayers were infected with EHEC strain 86-24 for 3 h.
Anti-nucleolin sera were added to the infected cells to label surfacelocalized nucleolin. The bacterial infection was allowed to proceed for an
additional 2 h, and the monolayers were then fixed and permeabilized.
Anti-nucleolin antibodies bound to nucleolin were detected with a
FITC-conjugated goat anti-mouse IgG secondary antibody (panels A–C).
Tir (B) and intimin-␥ (C) were detected with polyclonal rabbit or sheep
antiserum, respectively, and the appropriate Texas Red-conjugated secondary antibody after cell fixation and permeabilization. The arrows in
each panel denote representative bacterial microcolonies. A, phasecontrast image of bacteria adherent to HEp-2 cells (A1) and
fluorescence microscopy of the same field to show surface nucleolin
distribution (A2). The regions indicated by arrows (A2) were superim-

mouse anti-nucleolin antibodies could reduce adherence of
EHEC strain 86-24 to HEp-2 cells. First we tested the commercially available anti-nucleolin monoclonal antibody for its adherence-blocking activity. Because of the high level of surface
nucleolin expressed in actively dividing cells, confluent HEp-2
cell monolayers were selected for use in these studies to ensure
that the concentration of surface-expressed nucleolin was low
enough to be saturable with the anti-nucleolin sera. No reduction in EHEC O157:H7 adherence to HEp2 cells was evident in
the presence of the monoclonal anti-nucleolin antibody (data
not shown). We interpreted this finding to mean that the
nucleolin epitope recognized by the monoclonal antibody is
distinct from the site on nucleolin to which intimin-␥ binds.
Second, we evaluated mouse polyclonal anti-nucleolin sera
that we had been raised against SDS-PAGE-purified human
nucleolin. To demonstrate that the polyclonal sera was specific
for only nucleolin, HEp-2 cell extracts were separated by twodimensional gel electrophoresis (Fig. 5A) and probed with either a monoclonal anti-nucleolin antibody (Fig. 5B) or our
polyclonal anti-nucleolin sera (Fig. 5C). Examination of the
autoradiographs of the Western blots revealed that the monoclonal anti-nucleolin antibody and the polyclonal anti-nucleolin
sera recognized the same single-protein spot of 110 kDa. Therefore, we concluded that the polyclonal antisera specifically
bound nucleolin and no other HEp-2 cell proteins.
We then assessed the adherence-blocking activity of the
mouse polyclonal anti-nucleolin sera. As shown in Fig. 6, the
adherence-blocking capacity of the anti-nucleolin sera (Fig. 6B)
against GFP-expressing EHEC strain 86-24 was substantially
greater than that of normal mouse sera (Fig. 6A). To deplete
these sera of anti-nucleolin antibodies, identical dilutions of the
anti-nucleolin sera and normal mouse sera were incubated
with a preparation of purified nucleolin that had been subjected to preparative SDS-PAGE and blotted onto nitrocellulose. For each sample, the number of adherent bacteria is
presented graphically in Fig. 6C. Although the anti-nucleolin
polyclonal sera decreased the number of adherent bacteria by
approximately 7-fold, the same sera that had been depleted of
anti-nucleolin antibodies showed no blocking capacity above
that seen with normal mouse serum. Additionally, antibodies
specific for nucleolin were acid-eluted from the strips of immobilized protein and tested for blocking ability. These monospecific anti-nucleolin antibodies significantly (p ⬍ 0.00001) decreased the numbers of adherent bacteria when compared with
the antibodies that had nonspecifically bound to and been
eluted from the nucleolin strips after incubation with normal
serum (77 ⫾ 12 bacteria/10 cells for monospecific anti-nucleolin
antibodies and 124 ⫾ 16 bacteria/10 cells for the control antibodies from normal mouse serum).
Addition of the polyclonal anti-nucleolin sera 1 h before or
concurrent with the addition of bacteria was shown to provide
the highest level of blocking activity. When anti-nucleolin sera
were added to HEp-2 cells 2 h post-infection, the blocking
capacity of the anti-nucleolin antisera was reduced considerably. Typically, in EHEC O157:H7 adherence assays, intimately attached bacteria are not evident until 3– 4 h postinfection. The finding that the blocking capacity of polyclonal
posed and enlarged (4.5⫻ original magnification) to demonstrate the
coincidence of adherent bacteria with nucleolin staining (A3 and A4).
All micrographs were taken with a 40⫻ objective B, 100⫻ magnification
of a phase-contrast micrograph of adherent bacteria (B1). Fluorescent
microscopy of surface-expressed nucleolin (B2), Tir localized beneath
adherent bacteria (B3), and the two latter images superimposed to
indicate regions of overlap (B4). C, 100⫻ magnification of a phasecontrast micrograph of adherent bacteria (C1). Fluorescent microscopy
of surface-localized nucleolin (C2), intimin-␥ (C3), and the two staining
patterns superimposed (C4).
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FIG. 5. Two-dimensional gel electrophoresis reveals specificity of polyclonal mouse anti-nucleolin sera. Detergent-extracted
HEp-2 cellular proteins were separated first by isoelectric point then by
molecular weight in a conventional two-dimensional polyacrylamide
gel. A, silver-stained two-dimensional SDS-polyacrylamide gel of the
total protein that was blotted onto nitrocellulose. B, Western blot of the
HEp-2 cell proteins separated by two-dimensional SDS-PAGE (as in
panel A) and probed with monoclonal anti-nucleolin antibody. C, Western blot of the HEp-2 proteins separated by two-dimensional SDSPAGE (as in panel A) and probed with polyclonal anti-nucleolin sera.
Molecular weight markers (in kDa) are indicated on the right in each
panel.

anti-nucleolin was reduced if antisera were added after infection but before the appearance of intimately adherent bacteria
suggests that the antibodies interfere with the initial association between the bacteria and the host cell surface. If the
bacteria had established contact with the HEp-2 cell surface
prior to anti-nucleolin addition, then the antisera were not able
to block intimate adherence of EHEC. Finally, because the
polyclonal anti-nucleolin sera were neither bacteriostatic nor
cross-reactive with bacterial cell surface proteins, we believe
that the reduction in bacterial adherence to HEp-2 cells in the
presence of this reagent is attributable solely to the antisera
preventing or reducing the contact between the bacteria and
nucleolin on the host cell surface.
DISCUSSION

The question of whether intimin isolated from EPEC or
EHEC O157:H7 can directly bind to host cells without Tir, the
bacteria-encoded intimin-binding protein, has been the subject
of considerable controversy (7). In this investigation, we confirmed the findings of Frankel and colleagues (12, 35), who
previously reported Tir-independent interactions of several dif-
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FIG. 6. Anti-nucleolin antibodies block adherence of EHEC
O157:H7 to confluent HEp-2 cells. Quiescent HEp-2 cell monolayers
were treated with either a 1:100 dilution of anti-nucleolin antisera or an
equivalent amount of normal mouse sera 1 h prior to infection with
GFP-expressing EHEC strain 86-24. After 4 h of infection, nonadherent
bacteria were removed and cells were fixed with formalin. Fluorescence
micrographs of GFP-expressing bacteria bound to HEp-2 cells are
shown for cells treated with normal mouse sera (A) or with anti-nucleolin sera (B). Each image (obtained at a magnification of 40⫻) reflects a
field of ⬃50 HEp-2 cells. A 1:100 dilution of the pooled antisera was
depleted of anti-nucleolin antibodies by adsorption against purified
nucleolin protein immobilized on nitrocellulose. The same dilution of
normal mouse sera was also absorbed against purified nucleolin to
serve as a control. A total of 48 images like those shown in panels A and
B were obtained for respective samples, and the number of adherent
bacteria was counted in each image. The mean number of adherent
bacteria per 10 HEp-2 cells is presented in panel C for the 1:100 dilution
of whole sera (left columns) or sera depleted of anti-nucleolin antibodies
(right columns). The number of adherent bacteria remained essentially
unchanged when normal mouse sera (open columns) was absorbed
against nucleolin, whereas the blocking capacity of the anti-nucleolin
sera (shaded columns) was abolished when absorbed against purified
nucleolin, a finding that presumably reflects loss of anti-nucleolin antibodies. The error bars encompass the 98% confidence level for determination of the mean.

ferent intimin types with HEp-2 cells, and we extended these
observations by the identification of a candidate receptor for
intimin-␥ on HEp-2 cells. That nucleolin is in fact this receptor
is supported by four lines of evidence from this study. First, a
protein with an apparent molecular mass of 110 kDa that
bound intimin-␥ was isolated from HEp-2 cell extracts and
identified by amino acid sequence analysis as nucleolin. Second, immunofluorescent staining of nucleolin and bound intimin-␥ strongly suggests co-localization of the two proteins on
the HEp-2 cell surface. Third, as demonstrated by immunofluorescence, the sites of EHEC O157:H7 microcolony formation
on HEp-2 cells were coincident with areas of nucleolin expression on the cell surface. Fourth, antibodies raised against
nucleolin significantly reduced binding of EHEC O157:H7 to
HEp-2 cells, with the reduction in adherence most evident
when antibodies were added before or at the time of bacterial
infection. This last result indicates that the proposed nucleolin/
intimin-␥ interaction occurs early in the infectious process.
That nucleolin can be found not only in the nucleus but also
on the surface of cells has been reported previously (reviewed
in Ref. 42). Indeed, Deng et al. (47) have documented the
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FIG. 7. Depiction of bacterial adherence mediated by the adhesins invasin and intimin-␥. The host cell binding domains of invasin and
intimin-␥ are structurally related (60, 61) and show some similarities in interactions with host cells. Specifically, both invasin and intimin-␥ bind
to eukaryotic receptors that recognize the extracellular matrix protein laminin, and both proteins evoke an extracellular signaling response from
the host cell through receptor-mediated interactions with the cytoskeleton (8, 73). Invasin signals the host cell through ␤1 integrin, and this
interaction results in internalization of the bacterium. Intimin-␥ signals the host cell through Tir, an interaction that results in formation of an
actin-rich pedestal that intimately attaches the bacterium to the cell surface. Because of findings that nucleolin may be involved in transmission
of signals from the cell surface to the nucleus (42, 48, 54, 64), we propose that the interaction between intimin-␥ and nucleolin may also be involved
in the host cell response that leads to pedestal formation.

presence of nucleolin on the surface of HEp-2 cells, the cell line
used in this study. Furthermore, we observed that there was a
higher concentration of nucleolin on the surface of actively
dividing cells than on quiescent cells. This finding is consistent
with what is known about nucleolin and its turnover in cells,
specifically that nucleolin is integral to cell growth and when
cell division ceases nucleolin is down-regulated to very low
levels in the cell (53, 54). The significant difference in the levels
of surface nucleolin expression in active and quiescent cells as
noted in this investigation may in part account for the discordant results among published reports on the binding of intimin-␥
to uninfected host cells. Perhaps those investigators who observed Tir-independent binding of intimin to cells used subconfluent monolayers in their experiments, whereas researchers
who reported only Tir-dependent binding used cells at a higher
density for their studies (12, 29, 36).
Although we were able to block the binding of EHEC
O157:H7 to HEp-2 cells with polyclonal anti-nucleolin sera, we
were unable to demonstrate blocking of EHEC adherence with
polyclonal anti-Tir serum (data not shown). The latter observation suggests that the intimin-Tir interaction may not occur
until after the bacterium is associated with to the host cell
surface and that such an interaction may mask any surfaceexposed sites on Tir from the potential blocking activity of the
anti-Tir antibodies. The fact that Tir but not nucleolin was
present beneath tightly adherent bacteria suggests that the
interaction between intimin-␥ and nucleolin may become unnecessary once the bacteria are intimately adherent to the host
cell surface.
Our analysis showed that nucleolin bound to the carboxylterminal portion of intimin-␥, a region of intimin that contains
the putative host cell binding domain. We also demonstrated
that the interaction between purified intimin-␥ and surfacebound receptor gave an apparent dissociation constant of 9 ⫻
10⫺8 M. This affinity is ⬃10-fold lower than the association of
invasin with its eukaryotic receptor (58). Invasin is homologous
to intimin (13) and is used by Y. pseudotuberculosis to gain
entry into the host cell cytoplasm (11). Invasin binds to ␤1
integrin on the cell surface, and this interaction promotes uptake of the bacterium into the cell (14). Tran and Isberg (59)

have reported that mutations in invasin that decreased affinity
for the receptor also showed decreased numbers of bacteria
inside the host cell. EHEC O157:H7 is an extracellular pathogen. We speculate that the weaker affinity of intimin-␥ for its
eukaryotic receptor may help prevent bacterial internalization
by the host cell.
The host cell binding domain of intimin-␣ is structurally
similar to invasin despite little sequence similarity (34, 60, 61).
The structure of intimin-␥ has not been solved; however, based
on sequence similarities between intimin-␣ and intimin-␥, we
assume that intimin-␥ also shares a similar conformation. Research with invasin provides clues about specific interactions
that may occur between intimin-␥ and nucleolin. When invasin
is bound to ␤1 integrin, binding of the extracellular matrix
proteins fibronectin and laminin to these integrins is blocked
(58, 62). Invasin binding to ␣3␤1 integrin displaces laminin-5, a
result that suggests invasin and laminin-5 have sterically overlapping or identical binding sites (63). Nucleolin, like some
integrins, also binds laminin (46, 64). Specifically, nucleolin
binds the neurite-promoting site of the A chain of laminin-1
(46). This IKVAV sequence of laminin-1, when synthesized as a
peptide, promotes cell attachment, migration, and neurite outgrowth (65). Based on the structural similarities between intimin and invasin, and the finding that invasin and laminin
share the same binding site on integrin, we propose that intimin-␥ may occupy a position which overlaps the laminin
binding site on nucleolin. In pointing out these similarities, we
do not mean to imply that intimin-␥ and invasin share the
same laminin binding site. Rather, we are suggesting that
invasin and intimin-␥ have evolved to take advantage of two
separate laminin receptors on the host cell surface.
A hallmark feature of the A/E lesion produced by intiminbearing EHEC O157:H7 or EPEC involves outgrowth from the
host cell surface of an actin-rich pedestal that cups the bacterium (8). The current model for this pedestal formation involves recruitment of a host cell GTPase by Tir bound to intimin (66). In this model intimin plays a secondary role, acting
only to focus Tir beneath the bacteria. Our finding that intimin-␥ bound specifically to nucleolin has led us to speculate
that intimin-␥ may play an additional role in pedestal forma-
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tion. We propose that cell-bound intimin-␥ may trigger a response in the host cell similar to that which occurs when the
cell encounters laminin, e.g. the extension of filopodia from the
cell surface (65, 67–70). A similar proposal has been made by
Phillips et al. (71) to explain the observation that latex beads
coated with intimin-␣ induce the formation of microvillus-like
processes on the surface of HEp-2 cells. Based on these new
findings, we present the following model for EHEC adherence
(Fig. 7). Initially intimin-␥ on the surface of EHEC would bind
to nucleolin in a manner analogous to that of invasin binding to
␤1 integrin. This initial adherence, in conjunction with the
actions of other bacterial virulence factors (such as the EspA
filament (25)), would allow the bacterium to insert Tir into the
host cell membrane. Intimin-␥ association with both nucleolin
and Tir would then trigger a host cell response leading to
pedestal formation. This interaction would be similar to the
manner in which invasin signals through integrins (26) but
with a different outcome. Although our model is speculative,
activation of cellular signal transduction pathways through
both nucleolin and Tir would explain why intimin-␥ requires
both a eukaryotic receptor and a bacterially expressed binding
partner to facilitate formation of the pedestal. Overall, we feel
this research may increase the understanding of similarities
between the binding of intimin and invasin to host cell receptors and may suggest how members of this family of proteins
have been modified to accommodate different pathogenic
strategies.
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